{"id":"xzp-3287-letrozole-anastrozole","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Arthralgia/joint pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Bone loss/osteoporosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"XZP-3287 is combined with letrozole or anastrozole, which are aromatase inhibitors that reduce estrogen synthesis in postmenopausal women. The combination approach aims to enhance therapeutic efficacy in estrogen-dependent breast cancers by dual inhibition of estrogen signaling pathways. This strategy targets hormone receptor-positive breast cancer cells that depend on estrogen for growth.","oneSentence":"XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:55:00.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (postmenopausal women)"}]},"trialDetails":[{"nctId":"NCT05257395","phase":"PHASE3","title":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-03-14","conditions":"Advanced Breast Cancer","enrollment":397},{"nctId":"NCT04539496","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2018-05-22","conditions":"Metastasis Solid Tumors, Advanced Breast Cancer","enrollment":402}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XZP-3287+ Letrozole/Anastrozole","genericName":"XZP-3287+ Letrozole/Anastrozole","companyName":"Xuanzhu Biopharmaceutical Co., Ltd.","companyId":"xuanzhu-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer (postmenopausal women).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}